What is Anaveon?
Founded in 2017 and based in Switzerland, Anaveon is dedicated to advancing novel treatments by leveraging a deep understanding of immunology. The company operates within the highly competitive and innovative biotechnology sector, focusing on clinical-stage development. Its commitment to translating scientific discoveries into tangible therapeutic solutions positions it as a key player in the pursuit of treatments for significant unmet medical needs.
How much funding has Anaveon raised?
Anaveon has raised a total of $119.5M across 1 funding round:
Series B
$119.5M
Series B (2021): $119.5M with participation from Syncona, Novartis Venture Fund, Forbion, Pontifax, Pfizer Ventures, and Cowen Healthcare Investments
Key Investors in Anaveon
Syncona
Syncona is a FTSE250 company focused on building and funding healthcare companies that aim to provide transformative treatments. They manage a diversified portfolio of life science firms and focus on maximizing shareholder value through key value inflection points.
Novartis Venture Fund
The Novartis Venture Fund invests in innovative life science companies focused on biotechnology and biopharmaceutical therapeutics. They support a diverse portfolio of companies across North America and Europe, leveraging their expertise to foster innovation and drive patient benefits.
Forbion
Forbion is a global life sciences venture capital firm that sources, builds, and guides biotech and biopharmaceutical companies from early stage through clinical development. They invest across multiple fund strategies covering all stages of pharmaceutical drug development.
What's next for Anaveon?
The substantial enterprise-level financing and recent strategic investment indicate that Anaveon is likely in a scaling phase, poised for significant clinical advancements and potential market entry. This capital will be instrumental in advancing its pipeline through critical development milestones, potentially including late-stage clinical trials and regulatory submissions. The company's strategic focus on immunological therapies suggests a forward-looking approach to addressing complex diseases, with future growth likely driven by successful clinical outcomes and strategic partnerships within the pharmaceutical industry.
See full Anaveon company page
